A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients

Inclusion Criteria: * Prevalent patients (≥ 3 months on dialysis) treated with thrice weekly hemodialysis (HD) or hemodiafiltration (HDF) * Secondary hyperparathyroidism defined as PTH levels \> 9x ULN according to current KDIGO guidelines if therapy-naïve, or patients already treated with calcium receptor sensitizers with PTH \> 2x ULN * Albumin corrected calcium ≥ 2,08 mmol/l * Calcium concentrations of dialysate stable for at least 2 weeks prior to screening Exclusion Criteria: * Currently receiving treatment in another investigational device or drug study or participation in non-interventional studies * Current treatment with etelcalcetide (Parsabiv©) or treatment with etelcalcetide within 3 months prior to study inclusion * Patient has known sensitivity to any of the products or components of Parsabiv© * Patient has received a parathyroidectomy * Parathyroidectomy planned or expected during the study period * Elective kidney transplant scheduled during the study period * Therapy with bisphosphonates within the past 12 months * Therapy with denosumab within the past 6 months * Antacids containing aluminum, calcium, magnesium or bicarbonate * Patient has a history of symptomatic ventricular arrhythmias or Torsades de Pointes * Patient has a history of myocardial infarction, coronary angioplasty, or coronary arterial bypass grafting within the past 6 months prior to screening. * Pregnant or nursing (lactating) women